Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 7;12:65.
doi: 10.1186/s13223-016-0169-2. eCollection 2016.

Comprehensive Genetic Testing for Primary Immunodeficiency Disorders in a Tertiary Hospital: 10-year Experience in Auckland, New Zealand

Affiliations
Free PMC article

Comprehensive Genetic Testing for Primary Immunodeficiency Disorders in a Tertiary Hospital: 10-year Experience in Auckland, New Zealand

See-Tarn Woon et al. Allergy Asthma Clin Immunol. .
Free PMC article

Abstract

Background and purpose: New Zealand is a developed geographically isolated country in the South Pacific with a population of 4.4 million. Genetic diagnosis is the standard of care for most patients with primary immunodeficiency disorders (PIDs).

Methods: Since 2005, we have offered a comprehensive genetic testing service for PIDs and other immune-related disorders with a published sequence. Here we present results for this program, over the first decade, between 2005 and 2014.

Results: We undertook testing in 228 index cases and 32 carriers during this time. The three most common test requests were for X-linked lymphoproliferative (XLP), tumour necrosis factor receptor associated periodic syndrome (TRAPS) and haemophagocytic lymphohistiocytosis (HLH). Of the 32 suspected XLP cases, positive diagnoses were established in only 2 patients. In contrast, genetic defects in 8 of 11 patients with suspected X-linked agammaglobulinemia (XLA) were confirmed. Most XLA patients were initially identified from absence of B cells. Overall, positive diagnoses were made in about 23% of all tests requested. The diagnostic rate was lowest for several conditions with locus heterogeneity.

Conclusions: Thorough clinical characterisation of patients can assist in prioritising which genes should be tested. The clinician-driven customised comprehensive genetic service has worked effectively for New Zealand. Next generation sequencing will play an increasing role in disorders with locus heterogeneity.

Keywords: Genetic testing; Next generation sequencing; Primary immunodeficiencies.

Figures

Fig. 1
Fig. 1
a Number of gene tests requested annually (2005–2014), b Breakdown of different hospital services requesting genetic tests (2005–2014), c Paediatric and adult services of different specialities requesting genetic testing (2005–2014)

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Gathmann B, Mahlaoui N, Gerard L, Oksenhendler E, Warnatz K, Schulze I, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:116–126. doi: 10.1016/j.jaci.2013.12.1077. - DOI - PubMed
    1. Todoric K, Koontz JB, Mattox D, Tarrant TK. Autoimmunity in immunodeficiency. Curr Allergy Asthma Rep. 2013;13:361–370. doi: 10.1007/s11882-013-0350-3. - DOI - PMC - PubMed
    1. Carneiro-Sampaio M, Coutinho A. Early-onset autoimmune disease as a manifestation of primary immunodeficiency. Front Immunol. 2015;6:185. doi: 10.3389/fimmu.2015.00185. - DOI - PMC - PubMed
    1. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35:696–726. doi: 10.1007/s10875-015-0201-1. - DOI - PMC - PubMed
    1. Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood. 2010;116:3398–3408. doi: 10.1182/blood-2010-03-275909. - DOI - PMC - PubMed

LinkOut - more resources

Feedback